Klinikum Frankfurt (Oder) GmbH

Research at Klinikum Frankfurt (Oder) GmbH investigates disorders of the blood and lymph system, including myelodysplastic syndromes, acute myeloid leukemia, and multiple myeloma, aiming to refine transplant preparation and novel drug combinations.

• Transplant‑ready high‑risk MDS and oligoblastic AML
• Combination regimens for multiple myeloma
• Biomarker‑guided therapy selection

Five active studies led by seven investigators are evaluating new therapeutic options to improve survival and quality of life for patients with these blood‑related cancers.

The oncology program concentrates on aggressive B‑cell lymphomas such as diffuse large B‑cell lymphoma, follicular lymphoma, and high‑grade B‑cell lymphoma, exploring how targeted agents and dose‑adjusted chemotherapy can extend remission.

• Elderly patients with untreated DLBCL
• Lymphomas with specific genetic rearrangements
• Maintenance strategies after induction therapy

The site’s trials seek to personalize treatment based on disease biology, striving for longer progression‑free survival without added toxicity.

In the neurology division, investigators focus on Alzheimer’s disease, evaluating oral compounds that may reduce brain amyloid and delay cognitive decline in early‑stage patients.

• Safety and tolerability of novel oral agents
• Biomarker monitoring of amyloid accumulation
• Long‑term cognitive outcomes in prodromal AD

These studies aim to provide new therapeutic avenues for individuals at risk of dementia, complementing the hospital’s broader research portfolio.